Floatz logo

Dccr

SIM1 Deficiency Obesity

Soleno Therapeutics, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the SIM1 Deficiency Obesity cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Dccr is also rated in:

Prader-Willi syndromeDormant
BB
Indicative ·
70 / 100
View asset →
severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
obesity due to prohormone convertase I deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →